MarketLens

Amicus Therapeutics: A Rare Disease Gem Acquired

7 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

The $1.9 Billion Bet: Chiesi Acquires KalVista, Redefining Rare Disease Value

4 months ago

Are Amicus Therapeutics (FOLD) and Autoliv (ALV) Overlooked Opportunities

6 months ago

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

6 months ago

Is the Biosensor Market a Hidden Gem for Investors

5 months ago

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Travere Therapeutics CEO Eric Dube stepped down for health and family reasons, and the board unanimously appointed Bradley L. Campbell, former Amicus CEO, as president and CEO. The transition could af...

TVTX

Stock News•1 months ago

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics' valuation may not fully reflect upside from Sephience and potential ST-920 approval. Sephience drives 63% of product revenue, while ST-920, a late-stage Fabry gene therapy, could sig...

PTC

Stock News•2 months ago

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics' BLA for z-rostudirsen in exon 51 DMD received FDA Priority Review, with a PDUFA date of January 21, 2027, after the DELIVER trial showed statistically significant dystrophin increas...

DYN